{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:52:22Z","timestamp":1785466342787,"version":"3.56.0"},"reference-count":39,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["451221"],"award-info":[{"award-number":["451221"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["Access to Medicines"],"award-info":[{"award-number":["Access to Medicines"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Uptake of biosimilars has been suboptimal in North America. This study was undertaken to quantify the impact of various policy interventions (namely, new start and switching policies) on uptake and spending on biosimilar infliximab and etanercept in British Columbia (BC), Canada.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used administrative claims data to identify BC residents \u226518\u2009years of age with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and\/or plaque psoriasis who qualified for public drug coverage from January 2013 to November 2020. Using interrupted time series analysis, we studied the change in proportion spent on and prescriptions dispensed of biosimilar infliximab and etanercept out of the total amount per agent after new start and biosimilar switching policies were implemented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our study included 208,984 individuals living with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and\/or psoriatic arthritis, corresponding to 5,884 patients taking infliximab and etanercept. After the new start policy, we detected a small gradual increase in the proportion of dispensed biosimilar etanercept prescriptions of 0.65% per month (95% confidence interval [95% CI] 0.44, 0.85). The trend related to the proportion of total spending on biosimilar etanercept also increased (0.51% [95% CI 0.28, 0.73]). After the switching policy, there was a sustained increase in the proportion of dispensed biosimilar etanercept and infliximab prescriptions of 76.98% (95% CI 75.56, 78.41) and 58.43% (95% CI 52.11, 64.75), respectively. Similarly, there was a persistent increase in monthly spending on biosimilar etanercept and infliximab of 78.22% (95% CI 76.65, 79.79) and 71.23% (95% CI 66.82, 75.65), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We found that mandatory switching policies were much more effective than new starting policies for increasing the use of biosimilar medications.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.25099","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:14:26Z","timestamp":1675840466000},"page":"2011-2021","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis"],"prefix":"10.1002","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5027-8014","authenticated-orcid":false,"given":"Alison R.","family":"McClean","sequence":"first","affiliation":[{"name":"University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Cheng","sequence":"additional","affiliation":[{"name":"University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Bansback","sequence":"additional","affiliation":[{"name":"University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Clement","sequence":"additional","affiliation":[{"name":"University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"University of Toronto and Women's College Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Harrison","sequence":"additional","affiliation":[{"name":"University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Law","sequence":"additional","affiliation":[{"name":"University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"IQVIA Institute for Human Data Science.The global use of medicines 2022: outlook to 2026.2022. URL:https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/publications\/the-global-use-of-medicines-2022.pdf."},{"key":"e_1_2_6_3_1","article-title":"Patented Medicine Prices Review Board","author":"Government of Canada","year":"2018","journal-title":"Biologics in Canada. Part 1: market trends"},{"key":"e_1_2_6_4_1","unstructured":"IQVIA Institute for Human Data Science.Medicine use and spending in the US: a review of 2017 and outlook to 2022.2018. URL:https:\/\/www.iqvia.com\/insights\/the\u2010iqvia\u2010institute\/reports\/medicine\u2010use\u2010and\u2010spending\u2010in\u2010the\u2010us\u2010review\u2010of\u20102017\u2010outlook\u2010to\u20102022."},{"key":"e_1_2_6_5_1","unstructured":"IQVIA Institute for Human Data Science.Biosimilars in the United States 2020\u20132024: Competition savings and sustainability.2020. URL:https:\/\/www.iqvia.com\/insights\/the\u2010iqvia\u2010institute\/reports\/biosimilars\u2010in\u2010the\u2010united\u2010states\u20102020\u20102024."},{"key":"e_1_2_6_6_1","unstructured":"US Food and Drug Administration.Biosimilar development review and approval.2017. URL:https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-development-review-and-approval."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-022-00420-4"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.211478"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.3188"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41201"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11106"},{"key":"e_1_2_6_12_1","unstructured":"MurrinS for the US Department of Health and Human Services Office of Inspector General.Medicare Part D and beneficiaries could realize significant spending reductions with increased biosimilar use.2022. URL:https:\/\/oig.hhs.gov\/oei\/reports\/OEI-05-20-00480.pdf."},{"key":"e_1_2_6_13_1","article-title":"PhRMA: federal biosimilar payment policies are having a positive effect","author":"Hagen T.","year":"2020","journal-title":"AJMC"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41203"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20180008"},{"key":"e_1_2_6_16_1","unstructured":"British Columbia Ministry of Health.Biosimilar initiative for health professionals.2022. URL:https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner\u2010professional\u2010resources\/pharmacare\/prescribers\/biosimilars\u2010initiative\u2010health\u2010professionals."},{"key":"e_1_2_6_17_1","unstructured":"Government of Canada.Drug product database online query.2022. URL:https:\/\/health-products.canada.ca\/dpd-bdpp\/index-eng.jsp."},{"key":"e_1_2_6_18_1","unstructured":"Population Data BC British Columbia Ministry of Health.Medical Services Plan (MSP) payment information file. URL:https:\/\/www.popdata.bc.ca."},{"key":"e_1_2_6_19_1","unstructured":"Population Data BC Canadian Institute for Health Information.Discharge abstract database (hospital separations). URL:https:\/\/www.popdata.bc.ca."},{"key":"e_1_2_6_20_1","unstructured":"Population Data BC Canadian Institute for Health Information.National Ambulatory Care Reporting System data set. URL:https:\/\/www.popdata.bc.ca."},{"key":"e_1_2_6_21_1","unstructured":"Population Data BC British Columbia Ministry of Health.PharmaNet. Data Stewardship Committee. URL:https:\/\/www.popdata.bc.ca."},{"key":"e_1_2_6_22_1","unstructured":"Population Data BC British Columbia Ministry of Health.Consolidation File (MSP registration & premium billing). URL:https:\/\/www.popdata.bc.ca."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-003567"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_6_25_1","unstructured":"Government of Canada Canadian Institutes of Health Research.Sex and gender in health research.2021. URL:https:\/\/cihr-irsc.gc.ca\/e\/50833.html."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2012.3972"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25024"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20200319"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-021-00235-x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwz043"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.01.024"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1571296"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210742"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14997"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02765-3"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0380-x"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.625296"},{"key":"e_1_2_6_39_1","unstructured":"US Food and Drug Administration.Drugs@FDA: FDA\u2010approved drugs.2022. URL:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.34776"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.25099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:34:11Z","timestamp":1759419251000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.25099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/acr.25099"],"URL":"https:\/\/doi.org\/10.1002\/acr.25099","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"2022-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}